Investigators also glance to evaluate linvoseltamab in relapsed/refractory several myeloma as Component of the phase 3 LINKER-MM3 trial. Experimental: Dose expansion_sub-population 2_higher dose of niraparib MTDs and/or candidate RP2Ds for elimusertib employed in combination with niraparib at a greater fastened dose. , we in this article reveal that pharmacological ATR https://hatshepsutd443sdq7.wikimeglio.com/user